Sotagliflozin - Lexicon Pharmaceuticals/Sanofi

Drug Profile

Sotagliflozin - Lexicon Pharmaceuticals/Sanofi

Alternative Names: [14C]-LX4211; LP-802034; LX-4211; SAR 439954

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; Sanofi
  • Class Alcohols; Antihyperglycaemics; Cardiovascular therapies; Glycosides; Pyrans; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 1 diabetes mellitus
  • Phase III Cardiovascular disorders; Type 2 diabetes mellitus
  • Phase II Heart failure

Most Recent Events

  • 24 Jun 2018 Updated efficacy data from the phase III inTandem1 trial in Type-1 diabetes mellitus presented at the 78th Scientific Sessions of the American Diabetes Association (ADA-2018)
  • 11 Jun 2018 Phase-III clinical trials in Type-2 diabetes mellitus in USA (PO), Canada (PO) (NCT03521934)
  • 23 May 2018 US FDA accepts NDA for sotagliflozin for Type-1 diabetes mellitus for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top